Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Tuesday the European Patent Office has granted a key patent covering dosing regimens for its experimental multiple sclerosis treatment vidofludimus calcium, extending potential market protection for the drug candidate in Europe to 2038. The patent, EP3713554, protects label-relevant dosing regimens of vidofludimus calcium and broadly covers the compound and its salt, solvate and free acid forms when used according to the approved label, the company said. The protection could be extended potentially to 2043 if a Supplementary Protection Certificate is granted. The patent had previously been granted in the United States by the US Patent and Trademark Office in 2023. CEO Daniel Vitt said the European patent represents an important step in strengthening the company's intellectual property strategy for the drug candidate. “Receiving this key patent in Europe represents a highly important advancement in our global intellectual property stra
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]Yahoo! Finance
- Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus CalciumPR Newswire
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Analyst Actions
- 2/9/26 - HC Wainwright
IMUX
Sec Filings
- 3/4/26 - Form SCHEDULE
- 3/4/26 - Form D
- 3/2/26 - Form DEF
- IMUX's page on the SEC website